Since MCL-1 acts as a master regulator of apoptosis in various human malignancies, including melanoma [64,65], it is not excluded that a decrease in MCL-1 in WM266.4 cells with RIPK4 silencing may affect their susceptibility to BRAFi. Here, RIPK4 is linked to melanoma.